Where is Solid Biosciences headquartered?

Solid Biosciences is recorded with headquarters in Boston, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is Solid Biosciences publicly traded?

Yes — Solid Biosciences is listed as a public company with ticker SLDB on NYSE in SEC EDGAR-derived records.

What drugs are associated with Solid Biosciences?

We link 4 drug profile(s) where Solid Biosciences appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Solid Biosciences sponsoring?

Solid Biosciences is linked to 16 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Solid Biosciences as applicant?

2 USPTO PatentsView record(s) name Solid Biosciences or a normalized variant as applicant.

What pipeline phases does Solid Biosciences have in our database?

Phase distribution from linked programs: phase 2: 7, phase 3: 7, phase 1: 2.

How many US-approved drugs are linked to Solid Biosciences?

4 linked drug profile(s) include US approval status in openFDA-derived metadata.

Where does NovaPharmaNews source data on Solid Biosciences?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Solid Biosciences data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is Solid Biosciences data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Solid Biosciences Pharmaceuticals Company Profile

Name: Solid Biosciences intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: 500 Rutherford Ave, Third Floor, Boston, Massachusetts 02129, US
Founded: 2013
Employees: 155
Programs: 16
Drugs: 20
Patents: 2

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Solid Biosciences is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker SLDB. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Duchenne muscular dystrophy, Glioblastoma, Head and Neck Neoplasm, Sarcoma. NovaPharmaNews links 16 clinical program(s), 4 drug profile(s), and 2 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (7), phase 3 (7), phase 1 (2).

Company snapshot

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and add

4 approved product(s) across US/EU regulatory metadata.
16 active pipeline program(s) linked via ClinicalTrials.gov.
2 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Solid Biosciences. Not investment advice.

Top assets

View drugs (20) View projects (16)

Lead pipeline drugs

Active clinical programs

CWS-2007-HR Soft Tissue Sarcoma
Phase 3
IP Small Cell Lung Cancer
Phase 3
SGT-003 Duchenne Muscular Dystrophy
Phase 3
dactinomycin Sarcoma
Phase 3

Momentum

Proprietary activity score for Solid Biosciences.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 17 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Chinese Academy of

TA overlap score 40
Peer + 0 momentum

Alaunos Therapeutics

TA overlap score 26.8
Peer + 0 momentum

SUTRO BIOPHARMA

TA overlap score 22

Recent activity

Latest pipeline, patent, and corporate events for Solid Biosciences.

Jun 8, 2026 Clinical update
SGT-003-101 — Phase 2
Jun 8, 2026 Clinical update
CWS-2007-HR — Phase 3
Jun 8, 2026 Clinical update
IP — Phase 3
Jun 8, 2026 Clinical update
Erlotinib — Phase 2
Jun 8, 2026 Clinical update
Bevacizumab/Irinotecan — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Solid Biosciences?

Solid Biosciences is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker SLDB. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Duchenne muscular dystrophy, Glioblastoma, Head and Neck Neoplasm, Sarcoma. NovaPharmaNews links 16
Is Solid Biosciences publicly traded?

Yes. Solid Biosciences is listed with ticker SLDB on NYSE per SEC EDGAR records linked on this profile.
What drugs does Solid Biosciences develop or market?

We link 20 drug profile(s) where Solid Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/solid-biosciences#company-drugs.
What are the latest developments for Solid Biosciences?

In the last 12 months our linked public records show 16 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does Solid Biosciences focus on?

Solid Biosciences focuses on Duchenne Muscular Dystrophy, Duchenne muscular dystrophy, Glioblastoma based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Oncology

Infectious Disease